Netscientific Share Discussion Threads

[blakieboy7] 23/1/2024 07:58

Glycotest RNS

[blakieboy7] 23/1/2024 07:32

Dr Ilian Iliev, CEO of NetScientific, and Chair of Glycotest said:"We welcome this additional funding from Fosun. Complemented by the 2023 CLA, these investments demonstrate strong financial support as Glycotest continues to progress towards commercialisation, including in the US and China."EMV Capital securing this third party funding is a further example of our capital efficient investment model, allowing Glycotest to grow without reliance upon the NetScientific balance sheet, and deploying our Value Creation Services team to underpin that growth."

[loafofbread] 19/1/2024 18:18

From another feed.

In the B Riley interview Frank NEVER mentioned an offering just mentioned 2 types of funding. A partnership and a commercial partnership. Also did anyone notice how much the B Riley interviewer started smiling when Frank started talking about how big the TAM was (100 billion) and that no one at this point has any dominance yet and that WE have the ability to become the dominant player. This is all setting up to become a monster company over the next 3-5 years. Stay strong longs and imo you’ll be RICHLY rewarded.

Not many shares around where there are near term multiple catalysts that could double/triple the share price in one go.

If they don't come in ,well we stay at 50/60p and trundle on with the rest of the portfolio that is growing pretty well.

Happy to position myself for a £200K gain or a £20k bath!

[1gw] 19/1/2024 11:18

Still curious about this one. Listened to the PDSB presentation. In the last couple of minutes he addresses the elephant in the room - how are they going to fund these huge trials? Didn't give much away, beyond talking about being strategic about it and looking at a range of options including partnering, and acknowledging that they need to sort it out in the near term. The hope I think is that they could do a big partnering/licensing deal on the Phase 3s that would fund the trials without material dilution - and the biotech market does seem to be waking up again. But it's getting late in the day, with them hoping to finalise trial design and get going this quarter. So the investor bet seems to be do you believe they can get non-dilutive (or substantially so) funding for the Phase 3 trials or are they going to have to bite the bullet and do a big dilutive raise?

This from the 3Q23 results release in November:

"PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million. PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024. PDS Biotech expects to execute its current operational and research and development endeavors by obtaining additional capital, principally through entering into collaborations, strategic alliances or license agreements with third parties and/or additional public or private debt and/or equity financings. The Company has had and continues to provide, what the Company believes to be favorable development milestones to the market and has upcoming development milestones."

[blakieboy7] 19/1/2024 10:16

Eight P2!!! Just wow!

[blakieboy7] 19/1/2024 10:15

Thanks for summarising - I was curious as to what he said

[loafofbread] 19/1/2024 10:01

Outstanding presentation by Frank yesterday.

PDSB on the cusp of a $100B market!

Two P3 ready to go and eight P2.

PDSB will be $20+ this qtr and we will double. Simple

[blakieboy7] 09/1/2024 10:36

Kingston - this is a really useful bb for PDSB htTps://stocktwits.com/symbol/PDSB

[kingston78] 09/1/2024 09:47

Hi Loaf, what rumours about PDSB please?

[loafofbread] 05/1/2024 09:26

The buzz around Angle is great for the sector.

Don't forget we have 25% of Vortex.

Paul Jones, CEO of Vortex, commented:
"We are thrilled to welcome this new investment, enabled by EMV Capital's fund-raising support. It helps us accelerate our plans for a breakthrough in how CTCs can be used to inform oncology treatment and monitoring. Precision diagnostics in combination with innovations around targeted therapies are enabling remarkable progress in personalised medicine. We're determined that Vortex will play a major role in this space - in the short term at the interface to biopharma and in the long term, in partnership with clinical health systems worldwide."

[loafofbread] 27/12/2023 10:28

Good chance the IC chap will pick us again as part of his New Year portfolio as the value of our companies have gone from strength to strength but the share price has done SFA.

Not long before PDSB has to partner or sell out and Glycotest starts getting a bit of news.

[loafofbread] 15/12/2023 08:55

PDSB showing signs of life again.

[blakieboy7] 02/12/2023 15:46

We need to realise value sooner or later!

[loafofbread] 02/12/2023 14:15

Deeptech valued at zero in the recent results so safe to assume a valuation of £1M+ for our 30% stake after this fund raise.

Credit to NSCI for doing what they promised and adding value to the portfolio.

[kingston78] 17/11/2023 15:34

Even in difficult times I have seen several takeovers at significant premium to their current share prices (200% to 300%). The latest having been announced yesterday by Mars taking over Hotel Chocolat for £534 million.

I hope that one day as and when the portfolio companies become more mature either NSCI float them onto the stock market one by one, or sell them at a substantial profit to a private buyer. I am sure that this process will happen. Patience will be rewarded.

[blakieboy7] 17/11/2023 08:19

Agreed. We're still in first gear

[loafofbread] 17/11/2023 08:17

Much easier if they just posted a normal spread on NSCI.

Another £500K increase in PDSB.

NSCI share price is so far behind fair value it's unreal.

[blakieboy7] 16/11/2023 22:05

100k buy PDSB after hours

[wapper] 16/11/2023 16:24

PDSB moving up nicely last few minutes too

[blakieboy7] 16/11/2023 10:39

Nice to see the spread closing

[blakieboy7] 16/11/2023 07:55

I'm surprised no RNS

[kingston78] 15/11/2023 19:39

The following is an extract of an announcement by Cytovale reported by PR Newswire
Nov 15, 2023 1:03 PM GMT

Cytovale Secures $84 Million Series C to Advance Commercialization of Transformative Sepsis Diagnostic Tool

Norwest-led Financing Will Bring FDA-Cleared IntelliSep® Test to Hospitals Nationwide to Support Early Detection and Treatment of Serious Condition

a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC). The financing included participation from other new and existing investors, as well as the conversion of bridge notes. Cytovale will use the proceeds to bring its – ® – to more hospital emergency departments (ED) and health systems in the United States, addressing historical diagnosis lag time that makes sepsis the leading cause of death in U.S. hospitals.

[blakieboy7] 15/11/2023 18:50

Things seem to be moving in the right direction

[loafofbread] 15/11/2023 18:44

Looks like another valuation uplift coming tomorrow.

Cytovale just raised $84M for it's sepsis test.

On the books we have 1% valued at £400K, giving a company value of £40M!

Worth a damn sight more than £40M after that mega raise.